PDCD1 and melanoma: In melanoma models, combining anti‐PD1/anti‐PD‐L1 with nanomaterials to induce ferroptosis exposes tumour antigens, enhancing tumour cell immunogenicity and reinforcing immunotherapy effectiveness.